Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$43.47 USD

43.47
961,363

+0.46 (1.07%)

Updated Sep 16, 2024 12:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

by Zacks Equity Research

Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

    Merck Gets Priority Review for Yet Another Keytruda sBLA

    by Zacks Equity Research

    Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets FDA's priority review. If approved, it will expand the eligible patient population.

      Gilead's Rheumatoid Arthritis Drug Successful in Phase III

      by Zacks Equity Research

      Gilead (GILD) and partner Galapagos' rheumatoid arthritis candidate meets all primary and key secondary endpoints in first phase III study.

        Glaxo's Nucala Suffers Regulatory Setback, Gets CRL for COPD

        by Zacks Equity Research

        FDA issues a complete response letter to Glaxo's (GSK) application for label expansion of its asthma drug, Nucala for COPD.

          Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint

          by Zacks Equity Research

          Gilead's (GILD) ankylosing spondylitis candidate, filgotinib meets primary endpoint in phase II study.

            Novartis to Sell Sandoz's Dermatology Business to Aurobindo

            by Zacks Equity Research

            Novartis (NVS) looks to sell Sandoz's dermatology business in the United States and generic U.S. oral solids portfolio, to Aurobindo Pharma USA Inc., for $0.9 billion.

              Merck's Keytruda Gets Priority Review for Rare Skin Cancer

              by Zacks Equity Research

              Merck's (MRK) sBLA for Keytruda to expand its label for a rare form of skin cancer gets priority review from FDA.

                Mylan Suffers Several Setbacks: What's in Store in 2H18?

                by Zacks Equity Research

                Mounting competition and recent setbacks cast a pall over Mylan's (MYL) near-term performance.

                  AstraZeneca's Lupus Drug Misses Primary Endpoint in Study

                  by Zacks Equity Research

                  AstraZeneca's (AZN) phase III study, evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus, does not meet primary endpoint.

                    Merck (MRK) Receives FDA Approval for Two HIV Medicines

                    by Zacks Equity Research

                    Merck's (MRK) two new HIV-1 medicines, Delstrigo and Pifeltro, get approval in the United States.

                      Glaxo's Asthma Drug Gets EU Nod for Pediatric Population

                      by Zacks Equity Research

                      Glaxo (GSK) gains EU approval for asthma drug Nucala as an add-on treatment for severe refractory eosinophilic asthma in children.

                        Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus

                        by Zacks Equity Research

                        Novartis (NVS) & AbbVie (ABBV) get cancer approvals. Merck (MRK) gets FDA nod for two new HIV medicines.

                          Emergent (EBS) to Buy Narcan Maker Adapt Pharma for $735M

                          by Zacks Equity Research

                          Emergent (EBS) inks a deal to buy Adapt Pharma. This move will add the latter's popular Narcan nasal spray to its portfolio.

                            Novartis' Tafinlar/Mekinist Combo Gets EU Nod for 3rd Disease

                            by Zacks Equity Research

                            Novartis' (NVS) BRAF/MEK inhibitor combination, Tafinlar plus Mekinist, gets approval in the EU for adjuvant treatment of BRAF V600 mutation-positive melanoma.

                              Gilead's CAR-T Therapy Yescarta Gets Approval in Europe

                              by Zacks Equity Research

                              Gilead's (GILD) CAR-T therapy, Yescarta gets approval in Europe for adult patients suffering from relapsed or refractory DLBCL and PMBCL, after two or more lines of systemic therapy.

                                Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails

                                by Zacks Equity Research

                                Shares of Zai Lab (ZLAB) decline following the failure of a phase IIA study on its pipeline candidate, ZL-3101, for the treatment of atopic dermatitis.

                                  Novartis' CAR-T Therapy Kymriah Gets Approval in Europe

                                  by Zacks Equity Research

                                  Novartis (NVS) gets EC approval for CAR-T therapy, Kymriah, for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia.

                                    AstraZeneca's Bevespi Unimpressive in Phase III COPD Study

                                    by Zacks Equity Research

                                    AstraZeneca's (AZN) inhaler, Bevespi Aerosphere, fails to demonstrate superiority over Glaxo's Arono in a phase III COPD study.

                                      Novartis Breast Cancer Drug Meets Primary Goal in Phase III

                                      by Zacks Equity Research

                                      Novartis' (NVS) late-stage candidate, BYL719, meets primary endpoint in SOLAR trial on advanced breast cancer patients.

                                        J&J to Appeal as Judge Confirms Jury Order in Talc Case

                                        by Zacks Equity Research

                                        Johnson & Johnson's (JNJ) suffers setback as Missouri judge confirms talc lawsuit jury verdict. The company intends to appeal against the decision.

                                          Glaxo Stock Up This Year So Far: Will the Rally Continue?

                                          by Zacks Equity Research

                                          After a relatively strong performance so far this year, let's see how things are shaping up for Glaxo (GSK) for the rest of the year.

                                            The Zacks Analyst Blog Highlights: IBM, Texas Instruments, Glaxo, Simon Property Group and State Street

                                            by Zacks Equity Research

                                            The Zacks Analyst Blog Highlights: IBM, Texas Instruments, Glaxo, Simon Property Group and State Street

                                              Mark Vickery headshot

                                              Top Stock Reports for IBM, Texas Instruments & Glaxo

                                              by Mark Vickery

                                              Today's Research Daily features new research reports on 16 major stocks, including IBM (IBM), Texas Instruments (TXN) and Glaxo (GSK).

                                                Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic

                                                by Zacks Equity Research

                                                Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.

                                                  Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication

                                                  by Zacks Equity Research

                                                  Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.